ASAM/Ohio Waiver Training: Toledo, Ohio: March 27-28, 2020

Product not yet rated

   image       image    

 image

ASAM/Ohio Waiver Training

 Day 1: 8-Hour ASAM Treatment of Opioid Use Disorder Course

Friday, March 27, 2020 
8:30 am - 5:30 pm

Mercy Health – St. Anne Hospital

Meeting Room 3

3404 W. Sylvania Avenue

Toledo, OH 43623

Free parking is available in the surface lots around the hospital.
Complimentary valet parking is also available 7:00 a.m. to 5:00 p.m., Monday through Friday at the main entrance to the hospital.   

DAY 2: 4-Hour OhioMHAS Implementation Training

Saturday, March 28, 2020
8:30 am - 12:30 pm

Mercy Health – St. Anne Hospital

Meeting Room 3

3404 W. Sylvania Avenue

Toledo, OH 43623

Free parking is available in the surface lots around the hospital.
Complimentary valet parking is also available 7:00 a.m. to 5:00 p.m., Monday through Friday at the main entrance to the hospital.   

This course is offered in partnership with the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and Substance Abuse and Mental Health Service Administration (SAMHSA). The curriculum for this course has been specifically designed for Ohio licensed physicians, nurse practitioners, and physician assistants.

Welcome to the Ohio DEA DATA 2000 One and a Half Day Waiver Training. Please LOG IN or Create a New Account to register for the course. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

The 8-hour section of the training provided by the American Society of Addiction Medicine (ASAM) covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This course is SAMHSA-supported. 

The 4-hour section of the training provided by OhioMHAS is required to receive your reimbursement and will include training from experts around Ohio that will enhance the prescriber’s knowledge about opioid prescribing and buprenorphine policies (e.g., low-dose prescribing according to federal and state guidelines and DEA guidance on documentation). 

 Once you have completed the entire day and a half training, return to the ASAM e-Learning Center and complete the necessary steps listed in the "content" tab to obtain your reimbursement.  If you have any questions, please contact education@ASAM.org


Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.

For NPs (CE Credit through AANP): Click Here   

For PAs (AAPA Category 1 CME Credit): Click Here

Funding for this conference was made possible (in part) by the Ohio Opioid STR Project- 1H79TI080261-01 grant from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Key:

Complete
Failed
Available
Locked
Treatment of Opioid Use Disorder: Waiver Qualifying - Toledo, Ohio - Friday, March 27, 2020
03/27/2020 at 8:30 AM (EDT)   |  9 hours
03/27/2020 at 8:30 AM (EDT)   |  9 hours
Live Implementation Half-Day Training - Toledo, Ohio, Saturday, March 28, 2020
03/28/2020 at 8:30 AM (EDT)   |  4 hours
03/28/2020 at 8:30 AM (EDT)   |  4 hours
Complete Post-Course CME Evaluation
21 Questions
Download CME Certificate
Up to 8.00 medical credits available  |  Certificate available
Up to 8.00 medical credits available  |  Certificate available 8 Credits
Send your CME Certificate to SAMHSA
Apply For Your Waiver
Select the "Apply For Your Waiver" button to begin.
Select the "Apply For Your Waiver" button to begin. Providers, please follow this link to apply for your waiver:
Download W-9 Form
Open to download resource.
Open to download resource. Please complete W-9 Form and upload it in the next component.
Upload W-9 Form
Graded as Pass/Fail
Graded as Pass/Fail After downloading and filling out the W-9 form, please upload the completed document here. We will use this information to distribute your reimbursement.
Enter DEA X Number
1 Question
Upload Copy of DEA X Number
Graded as Pass/Fail | Due Date: 02/22/2020
Graded as Pass/Fail | Due Date: 02/22/2020 In order to receive your reimbursement, you must scan a copy of your DEA X Number and upload that file here. One this is uploaded, we will give you your reimbursement.
Need Help?
Contact Us
Contact Us If you need help or have questions about this process ​please email education@asam.org ​or call 301.656.3920 and ask to speak with an education team member​.

Click here for additional resources.

CME Information and Disclosure Listing

Date of Release: June 2018 

Approved Through: December 2020

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

NameNature of Relevant Financial Relationship
Dan Alford, MD, MPH, DFASAM, ChairNone
Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
Alta DeRoo, MD, FASAMNone
Soraya Azari, MDNone
Jill Mattingly, DHSc, MMSc, PA-CNone
Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
What was received: Honoraria
Role: Expert faculty for CME activities
Commercial Interest: Gilead
What was received: Honoraria
Role: Expert faculty for CME activities
Mary McMasters, MD, DFASAMNone
Yngvild K. Olsen, MD, MPH, DFASAMNone
Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
What was received? Stock 
Role: Advisor
Kristin Smith, DNP, FNP-C, AAHIVS None
Tricia E. Wright, MD, MS, FACOG, DFASAM None


ASAM CME Committee

NameNature of Relevant Financial Relationship
Catherine Friedman, MD (Chair)None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
What was received: Travel expenses
Role: Speaker
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRONone
Zwaantje H. Hamming, FNP-C, CARN-APNone
Herbert L. Malinoff, MD, FACP, DFASAM None
Noel Ilogu, MD, MRCP, DFASAMNone
Edwin A. Salsitz, MD, DFASAMNone
 ASAM Staff and Consultants
Arlene C. Deverman, MA, CAE, CFRENone
Marcia Jackson, PhDNone
Sandy MetcalfeNone


ASAM Medical Education Council

NameNature of Relevant Financial Relationship
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
What was received: Received free/discounted materials for research studies through an open tender process
Role: Research Studies
Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
What was received: Grant funds
Role: Principal investigator on research study
Commercial Interest: Johnson & Johnson E-NRT Advisory Board
What was received: Consulting Fees
Role: Consulting on Johnson & Johnson E-NRT Advisory Board
Daniel P. Alford, MD, MPH, DFASAMNone
Michael Fingerhood, MD, FACP, FASAMNone
Catherine R. Friedman, MD, FAPA, DFASAMNone
Adam J. Gordon, MD, MPH, FACP, DFASAMNone
Miriam S. Komaromy, MD, FACP, DFASAMNone
Edwin A. Salsitz, MD, DFASAMNone
Mark P. Schwartz, MD, DFASAMNone
Mark A. Weiner, MD, FASAMNone
 ASAM Staff and Consultants
Penny S. Mills, MBANone
Arlene C. Deverman, MA, CAE, CFRENone
Marcia Jackson, PhDNone
Dawn C. HowellNone
Molly S. MazukNone
Alexandra (Alli) UngerNone
Jennifer L. ButchartNone

Funding for this training was made possible (in part) by the Ohio State Opiate Response (SOR) grant #3H79T1081684-01S1 from SAMHSA. The views expressed in written materials or publications do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Funding for this initiative was made possible (in part) by grant no. 1H79TI026793-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

At the conclusion of this activity, learners should be able to:

  1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
  2. Identify and assess patients who are appropriate for treatment with medications
  3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
  4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

Licensed physicians, nurse practitioners, and physician assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.

Claiming CME Credit

  1. Under the “Contents” tab locate the step “Complete Post-Course CME Evaluation”
  2. Fill out the survey by clicking the blue “Fill out Survey” button
    1. Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window
  3. Submit the evaluation (the next box should activate, and the CME evaluation box should turn green with a white check mark)
  4. Click the button “Claim Medical Credits” in the box titled “Download CME Certificate”
  5. Choose the type of credit (Physician or Non-physician) and click submit
  6. Click the button “View/Print Certificate” to save or print your certificate
    1. Pro tip: If you ever lose your certificate, you can come back to the ASAM e-Learning Center and view it on your Transcript (found on Dashboard)


Apply

NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

Qualify

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.